Related Experiment Video
Updated: May 9, 2026

Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer
Published on: January 5, 2024
A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin
Jan Lankelma1, Rafael Fernández Luque, Henk Dekker
1Department of Molecular Cell Physiology, VU University, De Boelelaan 1085, Room G-226a, 1081 HV Amsterdam, The Netherlands. j.lankelma@vu.nl
Abstract:
Previous models for predicting tumor cell growth are mostly based on measurements of total cell numbers. The purpose of this paper is to provide a new simple mathematical model for calculating tumor cell growth focusing on the fraction of cells that is clonogenic. The non-clonogenic cells are considered to be relatively harmless. We performed a number of different types of experiments: a long-term drug "treatment", several concentrations/fixed time experiments and time-series experiments, in which human MCF-7 breast cancer cells were exposed to doxorubicin and the total number of cells were counted. In the latter two types, at every measurement point a plating efficiency experiment was started. The final number of colonies formed is equal to the number of clonogenic cells at the onset of the experiment. Based on the intracellular drug concentration, our model predicts cell culture effects taking clonogenic ability and growth inhibition by neighboring cells into account. The model fitted well to the experimental data. The estimated damage parameter which represents the chance of an MCF-7 cell to become non-clonogenic per unit time and per unit intracellular doxorubicin concentration was found to be 0.0025 ± 0.0008 (mean ± SD) nM(-1) h(-1). The model could be used to calculate the effect of every doxorubicin concentration versus time (C-t) profile. Although in vivo parameters may well be different from those found in vitro, the model can be used to predict trends, e.g. by comparing effects of different in vivo C-t profiles.
Related Concept Videos
Pharmacodynamic Models: Linear Concentration–Effect Model
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacodynamic Models: Emax Drug–Concentration Effect Model
Pharmacodynamic Models: Overview
